LncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer

被引：0
作者：
Yan Ma
Yang Di
Qiuyue Li
Qilin Zhan
Xiaomeng He
Shanshan Liu
Heng Zou
Christopher Corpe
Litian Chen
Jin Wang
机构：
[1] Fudan University,Shanghai Public Health Clinical Center
[2] Fudan University,Department of Pancreatic Surgery, Huashan Hospital
[3] King’s College London,Department of Hepatobiliary Surgery
[4] Nutritional Science Department,undefined
[5] Shanghai Jiaotong University School of Medicine Xinhua Hospital,undefined
来源：
Discover Oncology | / 13卷
关键词：
Pancreatic cancer; lncRNA; Metastasis; EMT; TGF-β/Smad; HIF-1α;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pancreatic cancer is the leading cause of cancer-related mortality because of tumor metastasis. Activation of the epithelial-to-mesenchymal transition (EMT) pathway has been confirmed to be an important driver of pancreatic cancer progression from initiation to metastasis. Long noncoding RNAs (lncRNAs) have been reported to exert essential physiological functions in pancreatic cancer progression by regulating the EMT program. In this review, we have summarized the role of EMT-related lncRNAs in human pancreatic cancer and the potential molecular mechanisms by which lncRNAs can be vital epigenetic regulators of epithelial to mesenchymal transition. Specifically, EMT-activating transcription factors (EMT-TFs) regulate EMT via TGF-β/Smad, Wnt/β-catenin, and JAK/STAT pathways. In addition, the interaction between lncRNAs and HIF-1α and m6A RNA methylation also have an impact on tumor metastasis and EMT in pancreatic cancer. This review will provide insights into lncRNAs as promising biomarkers for tumor metastasis and potential therapeutic strategies for pancreatic cancer.
引用
收藏
相关论文
共 121 条
  • [1] Rahib L(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921
  • [2] Khalaf N(2021)Burden of pancreatic cancer: from epidemiology to practice Clin Gastroenterol Hepatol 19 876-884
  • [3] Schizas D(2020)Immunotherapy for pancreatic cancer: a 2020 update Cancer Treat Rev 86 102016-348
  • [4] Neoptolemos JP(2018)Therapeutic developments in pancreatic cancer: current and future perspectives Nat Rev Gastroenterol Hepatol 15 333-2020
  • [5] Mizrahi JD(2020)Pancreatic cancer Lancet 395 2008-1057
  • [6] Li D(2004)Pancreatic cancer Lancet 363 1049-530
  • [7] Zheng X(2015)Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer Nature 527 525-175
  • [8] Turajlic S(2016)Metastasis as an evolutionary process Science 352 169-1813
  • [9] Swanton C(2019)Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants Mod Pathol 32 1806-412
  • [10] Hutchings D(2018)Epithelial mesenchymal transition in tumor metastasis Annu Rev Pathol 13 395-591
12345678910